Table 1.
Characteristics of patients.
| Characteristic | Co-reactivation group | Other reactivation group# | No reactivation group | P value |
|---|---|---|---|---|
| Gender, no.(%) | 0.91 | |||
| Male | 14 (58.3) | 83 (57.2) | 47 (60.3) | |
| Female | 10 (41.7) | 62 (42.8) | 31 (39.7) | |
| Age, median (range) | 29 (6–51) | 27 (1–61) | 35 (3–63) | 0.246 |
| Underlying disease, no.(%) | 0.22 | |||
| AML | 9 (37.5) | 57 (39.3) | 34 (43.6) | |
| ALL | 14 (58.3) | 66 (45.5) | 27 (34.6) | |
| SAA | 0 | 8 (5.5) | 8 (10.3) | |
| MDS | 1 (4.2) | 8 (5.5) | 8 (10.3) | |
| Other* | 0 | 6 (4.1) | 1 (1.3) | |
| Disease status | 0.496 | |||
| ≤CR2 | 23 (95.8) | 133 (91.7) | 69 (88.5) | |
| CR3 or NR | 1 (4.2) | 12 (8.3) | 9 (11.5) | |
| Donor-recipient relationship, no.(%) | 0.001 | |||
| Father | 13 (54.2) | 66 (45.5) | 20 (25.6) | |
| Mother | 1 (4.2) | 8 (5.5) | 4 (5.1) | |
| Sibling | 3 (12.5) | 45 (31) | 45 (57.7) | |
| Son/Daughter | 5 (20.8) | 23 (15.9) | 6 (7.7) | |
| Unrelated donor | 2 (8.3) | 3 (2.1) | 3 (3.8) | |
| HLA match, no.(%) | <0.001 | |||
| Haploidentical | 22 (91.7) | 133 (91.7) | 39 (50) | |
| Identical | 0 | 9 (6.2) | 36 (46.2) | |
| Unrelated donor | 2 (8.3) | 3 (2.1) | 3 (3.8) | |
| Blood type, no.(%) | 0.889 | |||
| Matched | 12 (50) | 80 (55.5) | 43 (55.1) | |
| Minor mismatched | 4 (16.7) | 29 (20) | 13 (16.7) | |
| Major mismatched | 5 (20.8) | 28 (19.3) | 15 (19.2) | |
| Major and minor mismatched | 3 (12.5) | 8 (5.5) | 7 (9) | |
| ATG used in conditioning therapy, no.(%) | 24 (100) | 138 (95.2) | 43 (55.1) | <0.001 |
| MNC, median (range), 108/kg | 8.21 (5.91–13.35) | 8.63 (4.3–15.67) | 8.45 (2.89–12.74) | 0.547 |
| CD34+ cell absolute count, median (range), 106/kg | 3.14 (1.06–7.48) | 2.41 (0.28–8.07) | 2.49 (0.97–6.06) | 0.409 |
| Donor gender, no.(%) | 0.148 | |||
| Male | 19 (79.2) | 117 (80.7) | 54 (69.2) | |
| Female | 5 (20.8) | 28 (19.3) | 24 (30.8) |
#Other reactivation group includes reactivation of CMV only, and reactivation of both CMV and EBV but does not fulfill definition of CMV and EBV co-reactivation
*Other underlying diseases include multiple myeloma (one patient), chronic myelomonocytic leukemia (two patients), chronic myeloid leukemia (two patients), acute heterozygosis leukemia (two patients).